spacer
home > pmps > winter 2003 > quality and risk management in botanical supply chains
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Quality and Risk Management in Botanical Supply Chains

Every company that uses plant-based ingredients in their products faces a number of sourcing challenges. Whether the product is a pharmaceutical grade drug or API; a personal care or 'cosmeceutical' product; a plant-derived medicinal extract a traditional herbal medicine or a functional food from a raw material sourcing perspective, the issues of quality, sustainability and traceability are remarkably similar. Techniques and processes devised to tackle these issues in relation to traditional medicines are very relevant even to manufacturers of pure plant-based compounds and derivatives. Many leading companies now recognise the importance of demonstrating efficacy to customers through the performance and documentation of clinical trials. Mounting scientific evidence can only serve the marketplace in a positive way. However, the validity of this data will be severely challenged if the basic plant raw materials are of an inadequate and variable standard, as this will affect the final product. The issues of quality, batch-to-batch variability and sustainability should be tackled in order to maintain consumer confidence.

Trends in Botanical Materials Usage and Regulation

Over the past 10 to 20 years, plant-derived products have enjoyed differing fortunes according to the market sector. Despite the unrivalled chemical diversity of the plant kingdom and past successes in drug development from morphine to Taxol, pharmaceutical companies have been drawn away from natural products by the allure of combinatorial chemistry and high-throughput screening. The reasons for this are complex but include a belief in greater returns per unit of expenditure, better control over intellectual property (IP), and a realisation of the inherent difficulties in managing a plant-based supply chain.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Trevor Theobald, Business Development Director, Indira Walker, Quality and Regulatory Affairs Director, and Dr Christopher Stewart, Botanical Sourcing Manager, at Kings

Dr Trevor Theobald is Business Development Director at Kings. He has many years' experience in both R&D and business development roles in the natural products and extracts arena with Courtaulds and British Sugar before joining Kings.


Indira Walker is Quality and Regulatory Affairs Director at Kings. She was UK/Eire Quality Manager/Qualified Person for Pharmacia Ltd and has QA and Regulatory experience at Daiichi Pharmaceuticals, Eli Lilly and Fisons plc.


Dr Christopher Stewart is Botanical Sourcing Manager at Kings. Previously with Oxford Natural Products, he has experience in managing crop development projects in the UK, Vietnam, the Caribbean and the Philippines.


spacer
Dr Trevor Theobald
spacer
spacer
spacer
Indira Walker
spacer
spacer
spacer
Dr Christopher Stewart
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IATA CEIV Pharma certificate of Turkish Cargo renewed

Turkish Cargo, the air cargo brand flying to the most countries around the world, extended the validity period of its IATA CEIV (Center of Excellence for Independent Validators) Pharma certificate to 2022, proving its success in all processes throughout the air transportation of medicinal products.
More info >>

White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>

 
Industry Events

FlyPharma Europe

22-23 October 2019, Copenhagen, Denmark

The FlyPharma Conference Europe 2019 is aimed at forward-thinking individuals and businesses that are ready to uncover the potential in their pharma supply chain. The event offers an interactive platform to discuss current and future challenges within pharma and cargo, with topics including market trends, cold chain innovations, latest regulatory demands, security technology, and how to encourage collaboration between supply chain players. There will be plenty of networking opportunities, including a complimentary evening networking event, where delegates can meet and catch up with senior and executive pharma and cargo professionals gaining strong, new industry contacts and building on existing ones.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement